Avadel Pharmaceuticals sees FY25 net product revenue $240M-$260M

Avadel has invested in expanding its field sales team to reach more physicians, doubling its field reimbursement team to accelerate the pace of patient fulfilment, providing more direct personal support to patients and physicians via an expansion of its nurse team, and adding patient ambassadors to help educate people with narcolepsy. Avadel expects to generate $240-$260M in net product revenue and cash flow of $20 – 40M during 2025, as the number of patients on LUMRYZ is expected to grow to 3,300 – 3,500. Additionally, Avadel is advancing its pivotal Phase 3 trial for idiopathic hypersomnia, which the company expects will further solidify its leadership in sleep medicine.